David Gill

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (theranostic) radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients.

Novum Medical is dedicated to bringing the next generation of technology to the spine and musculoskeletal market. Our development efforts focus on using novel biomaterials to design innovative orthopedic implants that have the potential to help patients live healthier, more productive and active lives.

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (theranostic) radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Allucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics and clinical pharmacology across a variety of therapeutic areas. With more than 30 years of experience in over 60 countries, Allucent’s individualized partnership approach provides experience-driven insights and expertise to assist its clients in successfully navigating the complexities of delivering novel treatments to patients.

Bridge to Life was founded with the mission of improving organ transplants through licensing and developing new preservation solutions and technologies to provide the highest quality of service to organ procurement organizations and transplant centers. Bridge to Life is a leading supplier of preservation solutions globally with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, we continue to explore emerging science and preservation technologies.

huMannity Medtec (The Alfred E. Mann Foundation for Scientific Research) is a non-profit organization dedicated to pioneering life-enhancing medical technologies for undermet healthcare needs. At huMannity, we strive to find solutions for medical problems that often have few other treatments. In our non-profit environment, we are free to take on long-term, high-risk challenges as well as to develop technology that can benefit those who suffer from conditions that have smaller populations of patients and groups who may not receive the attention paid to higher-profile diseases or injuries. Our talented and diverse staff and our world-class research facility allow us to take development from the seed of an idea through prototyping and quality control all the way to manufacturing a device that can be used in a clinical trial. See more at humannitymedtec.org

Novum Medical is dedicated to bringing the next generation of technology to the spine and musculoskeletal market. Our development efforts focus on using novel biomaterials to design innovative orthopedic implants that have the potential to help patients live healthier, more productive and active lives.